A
Acellular pertussis 237
Acid-fast bacillus 162
Acquired immune deficiency syndrome 236
Actinic dermatitis, chronic 293
Adalimumab 4, 8, 9, 21, 54, 61–62, 67, 136, 137, 141, 158, 164, 167, 168, 171, 184, 185, 190, 191, 207, 208, 213, 260, 278, 280, 282
dosage of 186t
Adaptive immunity 37
Adenosine triphosphate 288
Adverse fetal outcome, risk of 276
Alopecia tool, severity of 292
Alopecia totalis 292
Alopecia universalis 292
American Thoracic Society 228
Anaphylactic reactions 212
Anemia 310
Angiofibromas 307
Angiogenesis 35
Annular erythema 201
Anorexia 310
Antiaging agents 310
Antibody-dependent cell-mediated cytotoxicity 128
Antiglomerular basement membrane disease 282
Antihistaminics 282
Anti-IgE monoclonal antibody 118
Anti-interleukin-17 blockers 277
Antilymphocyte function-associated antigen-1 9
Anti-secukinumab antibodies 75
Antiviral therapy 283
administration 300
adverse reactions 301
chemical structure of 298f
contraindications 301
current evidence 300
dosage 300t
dose adjustment 302
drug interactions 302
investigations 302
mechanism of action 299
pharmacology 298
special situations 302
uses 299
Arthropathy spondyloarthropathy 190
Aseptic meningitis 212
Autoantibodies 212
Autoimmune blistering diseases 101
Autoimmune disorders 175
Autoimmune hemolytic anemia 101
Autoimmune neuropathies 101
Autoimmune thrombocytopenia 101
Autoimmune urticarial, chronic 129
B
Bacterial infection, secondary 112
Basiliximab 9
Belimumab 198
Bevacizumab 3
Bicytopenia 66
Bioequivalence 14
Biologic therapy 243
Biological medicinal products 14
Biomimics 16
Breastfeeding 77
Breath, shortness of 227
Bridging therapy 163
British Isles Lupus Activity Group 197
Bronchial asthma 119
Bronchospasm 208
Bullous eruptions 211
Bullous systemic lupus erythematosus 145
Burkitt's lymphoma 109
C
Calcineurin 304
Canakinumab 184
Candidiasis 76
Carbamazepine 302
Cardiac disease 283
Central nervous system, disorders of 263
Certolizumab pegol 9
Cetirizine 278
Chest pain 227
Chills 208
Chimeric antibodies 7
Chinese hamster ovary 61
Cholestatic liver disease 212
Chronic plaque psoriasis, efficacy of infliximab in 53t
Churg-Strauss syndrome 138
Coiled-coil alpha-helical rod protein-1 31
Collagen vascular dermatoses 4
Community acquired pneumonia 209
Concomitant therapy 163
Continuous therapy 53
Conventional therapy 154
Cord blood levels 68
Corneodesmosin 31
Coronary spasm 283
Corticosteroid
6-mercaptopurine 233
azathioprine 233
low-dose 233
methotrexate 233
synergistic effect with 127
Cough 227
C-reactive protein 113
Crystallizable fragment 128
Cutaneous adverse reactions, severe 4
Cutaneous lymphocyte-associated antigen 33
Cutaneous sarcoidosis 137
Cutaneous ulcerations 211
D
Daclizumab 9
Defective skin barrier, presence of 32
Dendritic cell 128
Denileukin diftitox 10
Deoxyribonucleic acid 269
Dermatitis 215
Dermatological diseases 293
Diabetic foot ulcer 11
Dimeric fusion protein 43
Diphenhydramine 107
Disfavor etanercept 190
Disseminated molluscum 294
Doucas and Kapetanakis, eczematid-like purpura of 211
Doxorubicin 112
Dupilumab 96
Dysrhythmia 209
Dystrophic nails, chronic 310
E
Earache 215
Elevated lactate dehydrogenase 107
Entecavir 283
Eruptive squamous cell carcinoma 294
Erythroderma 169
Etanercept 4, 10, 21, 43–45, 136, 137, 142, 158, 164, 167, 171,184, 187, 190, 193, 207, 208, 212, 259, 278
dosage of 187t
in psoriasis, efficacy of 45t
European Academy of Dermatology and Venereology Guidelines 127
European Dermatology Forum 103
European Scleroderma Trial and Research Group 200
Exfoliation 211
F
Facial angiofibromas 305
Fatal sepsis 110
Fatigue 215
Fibroblast growth factor 305
Flaccid vesiculobullous lesions over skin and mucosae 175
Fluid overload, risk of 132
Flu-like symptoms 213
Foliaceous 129
Follicular hyperkeratosis 182
G
Galiximab 10
Gastritis 209
Genodermatoses 306
Geriatric population 275
Gillian classification 196
Glucocorticoid replacement therapy 233
Granulocyte-macrophage colony- stimulating factor 127
H
Heart failure, severe 109
Heliotrope rash 199
Hemoptysis 227
Hepatic impairment 122
Hepatitis 191
B core
antigen 106
total antibody 157
B envelope
antibody 266
chronic 283
B reactivation 66
B surface
infection 109
infection, diagnosis of 266t
surface antigen 162
infection, reactivation of 283
Herceptin 3
Heterogenous group of immune disorders 120
Hidradenitis suppurativa 22, 44, 54, 61, 62, 64, 136, 137, 139, 142, 182, 182, 182f, 184f, 188, 189, 208, 221
management of 182
Hormonal therapy 183
Human antibodies 7
Human antichimeric antibodies 108
Humanized antibody 7
Humoral immunity 112
Hurley's staging system 183
Hypercholesterolemia 310
Hypereosinophilic syndrome 293
Hyperkalemia 107
Hyperphosphatemia 107
Hypertension 310
Hypertriglyceridemia 310
Hyperuricemia 107
Hypocalcemia 107
Hypotension 208
I
Idiopathic pancreatitis, acute 212
Immunization 58
Immunoadsorption 101
Immunobullous diseases, management of 175
Immunodeficiency, primary 138
Immunological synapse 33t
Immunosuppression 233
In vitro studies 18
Inflamed skin 33
Inflammatory dermatoses 129
Inflammatory pathway, multiple 44
Infliximab 4, 8, 9, 20, 21, 52, 55, 136, 139, 165, 167, 168, 184, 190, 192, 208, 211, 260, 277, 279, 280, 282
dosage of 185t
Infusion reactions, acute 207
Innate immunity 37
Intermittent therapy 53
International Psoriasis Consortium 22
International Psoriasis Council 15
vaccination with 235
Invasive fungal infections 57
Isoniazid 162
Itch severity score 291
L
Lamivudine 283
Lebrikizumab observations 91
Leg ulcer 11
Legionella 211
Leukocytoclastic vasculitis 211
Linear IgA bullous dermatoses 129
Lipocalin 82
Livedoid vasculopathy 129
Local lymph nodes 32
Loratadine 278
Lupus erythematosus 293
Lymphangiomatosis 307
Lymphatic malformations 307
Lymphocyte cell adhesion molecule, activated 84f
Lymphocyte function antigen 33
Lymphocytic leukemia, chronic 101
Lymphoma 108
Lymphomatoid granulomatosis 102
M
Macrophages 39
Malignancy, prior 191
Malignant tumor 77
Mantoux conversion 225
Mast cells 39
Maternal immune system 275
Maturation of T-cells 33
Metabolic syndrome 190
Metastatic melanoma 11
Methylsulfonyl 298
Migration 33
Mitogen-activated protein kinase 81
Molecular weight 100
Monogenic disease 31
Moraxella 211
Multiforme 293
Munro's microabscess 34
Murine monoclonal antibody 118
Muromonab 207
Mycobacterium bovis infection 222
Myocardial infarction 283
Myocardial ischemia 209
N
National Cancer Institute 106
National Psoriasis Foundation 170
Natural products 1
Nausea 208
Necrobiosis lipoidica 137
Necrobiotic xanthogranuloma 129
Necrotizing fasciitis 211
Neonatal cytopenia, cause 278
Nephrotoxic 281
Neurofibromatosis 306
Neurologic, side effects 132
Neurological event 66
Neutrophil accumulation, role in 34
Neutrophils 39
New York Heart Association 66
Newer biologics 89
Nomenclature 19
Non-Hodgkin B-cell lymphoma 221
Nonhuman amino-acid residues 118
Noninfectious uveitis, chronic 72
Nonsteroidal anti-inflammatory drug 281
Nucleotide-binding oligomerization domain 32
O
Obinutuzumab 113
Obstructive pulmonary disease, chronic 299
Optic neuritis 209
Oral phosphodiesterase-4 298
Ortho biotech's muromonab-CD3 3
P
Pachyonychia congenita 306
Palmoplantar pustulosis 293
Papa syndrome 62
Paracetamol 107
Parvovirus B19 108
Pathogen-associated molecular patterns 32
Pediatric patients 122
Pemphigoid gestationis 129
Periodic fever syndromes 259
Peripheral blood mononuclear cells 299
Phagocytosis 100
Pharyngitis 215
Phenytoin 302
Physical trauma 30
Pitrakinra, mechanism of action 91
Plasmacytoid dendritic cells, activation of 36
Pleuritis 209
Pneumococcal polysaccharide vaccine 236
Pneumococcal vaccine 236
Pneumocystis carinii pneumonia 209
Polyarticular arthritis 209
Polychemotherapy 109
Polygenic disease 31
Preexisting hypogammaglobulinemia immunosuppressant 108
Pretibial myxedema 129
Prolonged neutropenia 210
Proteins, antimicrobial 32
adherence 46
biologic therapy for 249t
combination therapy 44
continuous vs intermittent therapy 45
development and severity of 31
drugs used in 261t
etiology of 29
susceptibility 31
management of 64t
Psoriatic lesions 30
Psychological stress 30
PTEN hamartoma syndrome 306
Pulmonary lymphangiomyomatosis 307
Pyelonephritis 209
Pyogenic arthritis 62
R
Rapamycin, mammalian target of 305
Rapamycin-immunophilin complex acts 304
Rasmussen's encephalitis 101
Recalcitrant subcorneal pustular dermatosis 139
Refractory nephrotic syndrome 110
Regulatory T cells 37
Reiter's disease 53
Reiter's syndrome 55
Relapsing polychondritis 44
Rescue therapy 163
Reticuloendothelial system 100
Retinoids 183
Rheumatoid vasculitis 202
Ribonucleic acid 271
Rifampicin 302
Rituximab 3, 9, 21, 100–102, 106, 107, 109, 110, 112, 113, 136, 138, 144, 177, 179, 197, 200, 207, 208, 237, 251, 254, 255, 262, 268, 272, 277, 279, 280, 283
dermatological uses of 102
dosing of 178
for pemphigus in
children 178
pregnancy 178
in pemphigus, use of 179
induced hypogammaglobulinemia 108
therapy 106
Rituximab-cyclophosphamide 112
Rodnan skin score, modified 200
Rotational therapy 163
S
Sartorius staging system 183
Scalp psoriasis 169
Scleromyxoedema 129
administered to breastfeeding women 77
administration 74
adverse effects 75
contraindications for 76
effect of fertility 77
in studies, clinical response to 73t
monitoring during therapy 75
pharmacology 71
special situations 76
treatment 73
uses 72
Serum creatinine 157
Sézary syndrome 11
Sinus tachycardia 209
Sinusitis 213
Siplizumab 9
Sneddon-Wilkinson disease 142
Squamous cell carcinoma 190
Steroid sparing agents 175
Steroid-resistant nephrotic syndrome, management of 263
Streptomyces hygroscopicus 304
Systemic antibiotics 183
Systemic steroids 175
T
Tasocitinib 287
Tenofovir 283
Teratogenicity 276
Th1 cells 37
Th1 driven disease 36
Th22 cells 37
Thiopurine methyltransferase enzyme 177
Thromboembolic events 132
Thymidine phosphorylase 35
Thyroglobulin 126
TNF blocking agents 10f
TNF inhibitors, case of 22
TNF-α blockers 68
basic information 293
citrate 288
contraindication 294
observations 95
pharmacology 288
special situation 295
uses 289
warning and precautions 294
Tralokinumab 91
Transaminitis 212
Transcription pathway, activator of 288f
Transepidermal water loss 36
Transplant recipients, chemoprevention in 308
Trastuzumab 3
Trophoblast cell 277
Tuberous sclerosis 305
Tumor lysis syndrome 107
Tumor necrosis factor-beta 43